Datavant and Boehringer Ingelheim Expand Partnership to Enhance Real-World Evidence Infrastructure NEW YORK -- (BUSINESS WIRE) -- Datavant, a leading health data platform company, has announced an expanded partnership with pharmaceutical giant Boehringer Ingelheim. The collaboration is aimed at boosting the pharmaceutical company's real-world evidence (RWE) initiatives by leveraging Datavant’s advanced privacy-preserving tokenization and connectivity technologies. Through this enhanced partnership, Boehringer Ingelheim will integrate Datavant's solutions into 75 additional clinical trials and several new molecular entities (NMEs). A key tool in this collaboration is Datavant Connect, which is powered by AWS Clean Rooms. This platform enables efficient exploration and assessment of third-party data sources without moving or sharing the underlying data, thereby streamlining the processes of data discovery, transformation, and linkage within a secure environment. The significance of this collaboration lies in its ability to provide deeper insights into the patient journey. By securely connecting diverse data sources, Boehringer Ingelheim can gain more comprehensive and precise information on treatment effectiveness, economic implications, and long-term health outcomes. This, in turn, aids in developing more personalized and cost-effective treatments, ultimately improving patient care. Arnaub Chatterjee, General Manager and President of Life Sciences, Ecosystem, and Public Sector at Datavant, commented on the partnership's potential. "We are thrilled to be part of Boehringer Ingelheim’s innovative data strategy, which is poised to revolutionize patient care. By facilitating secure and scalable data linkage, we are helping set a new standard in medical research. This collaboration demonstrates the transformative power of technology in healthcare, driving better patient outcomes." Paul Petraro, Executive Director and Head of the Real World Evidence Analytics Center of Excellence at Boehringer Ingelheim, echoed Chatterjee’s sentiments. "Our commitment to using cutting-edge technologies in real-world data reflects our dedication to advancing medical research. Expanding this approach across a broader range of trials and commercial launches will help us develop more targeted and cost-effective treatments, ultimately transforming patient care." To ensure smooth integration with Boehringer Ingelheim’s current research infrastructure, the implementation of Datavant’s tokenization technology will occur in phases. The goal is to create a robust framework that not only guides future studies but also serves as a model for other industry players looking to adopt a similar RWE strategy. About Datavant Datavant is a health data platform company dedicated to making the world’s health data secure, accessible, and actionable. The firm offers a proprietary platform and network that facilitates critical solutions across the healthcare ecosystem. Currently, Datavant enables the movement of more than 60 million healthcare records between thousands of organizations, including over 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an extensive network of over 300 real-world data partners. For more information, visit datavant.com. About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company committed to improving human and animal health. As one of the top investors in research and development, the company focuses on developing innovative therapies that address high unmet medical needs. Founded in 1885 and remaining independent, Boehringer Ingelheim has taken a long-term, sustainable approach, integrating sustainability into every aspect of its operations. With over 53,500 employees serving more than 130 markets, the company is dedicated to building a healthier, more sustainable, and equitable future. For more details, visit www.boehringer-ingelheim.com/us.